GeoVax to initiate Phase 1 combination therapy trial with MVA62B
Category: #health  By Pankaj Singh  Date: 2020-08-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

GeoVax to initiate Phase 1 combination therapy trial with MVA62B

GeoVax Labs, Inc., a U.S-based biotechnology firm that focuses on vaccines and immunotherapies for cancer and other infectious, has recently revealed that it has initiated the Phase 1 clinical trial of combination therapy in HIV-infected adults. The combination therapy will be using the company’s new boost component MVA62B. 

Reportedly, the trial would involve active participation of various researchers that will be led by Dr. Steven Deeks, a professor at the UCSF and a faculty member at the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. The study is being funded by The Foundation for AIDS Research, amfAR. The main motive of this study is to induce remission in patients suffering from HIV.

According to reports, the trial would enroll 20 HIV-positive patients who are on effective and stable antiretroviral therapy (ART). GeoVax will be offering MVA62B, a novel boost component that would be combined with its HIV prevention vaccine, GOVX-B11.

Speaking on the move, Dr. Steven Deeks said that this Phase 1 study would come as one of the most inclusive trials till this date to evaluate the efficiency of synergistic methods to regulate HIV infection. The main focus here is to test the tolerability and safety of the combination therapy and to analyze the viral load ’set-point’ in between of a treatment interruption. 

Meanwhile, the secondary endpoint emphasizes on determining changes in viral reservoir status and immune responses. The institute is delighted to partner with GeoVax for this study and is looking forward to collaborating with GeoVax scientists to progress this trial. 

As for Harriet Robinson, Ph.D., CSO Emeritus, GeoVax, the company has managed to previously establish the result of its HIV vaccine and hopes to see the same progressive result for UCSF’s therapeutic study where it would be combined with its MVA62B vaccine. 

Source Credit: https://www.globenewswire.com/news-release/2020/08/24/2082657/0/en/GeoVax-Announces-Clinical-Trial-Initiation-of-Novel-Combination-Therapy-Utilizing-MVA62B-to-Induce-Remission-in-HIV-Positive-Patients.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Dada Group partners with Ferrero for new snack food retail model
Dada Group partners with Ferrero for new snack food retail model
By Pankaj Singh

The new retail model will help Ferrero improve brand reach to younger online customers in China

Chinese on-demand delivery and retail platform, Dada Group has inked...

Aphena Pharma to complete expansion of Solid Dose Division by April
Aphena Pharma to complete expansion of Solid Dose Division by April
By Pankaj Singh

Aphena Pharma Solutions, a pharmaceutical services provider, has reportedly announced the continuous expansion of its Tennessee-based Solid Dose Division worth $21 million. This division is expected to be completed by ...

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...